Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18757539 | PREPARATION OF A PHOSPHOLIPID COMPOSITION/NANO LIQUID PRODUCT USEFUL IN TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALING | June 2024 | October 2024 | Allow | 4 | 1 | 0 | No | No |
| 18750994 | COMPOSITIONS FOR INHIBITING ANAEROBIC MICROORGANISMS | June 2024 | November 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18418822 | METHODS FOR TREATMENT OF MENOPAUSAL SYMPTOMS | January 2024 | April 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18400485 | METHODS OF FORMING BIOCHEMICAL SCAFFOLDS FOR ENHANCING MENTAL FUNCTION AND ACUITY | December 2023 | February 2025 | Allow | 14 | 0 | 0 | Yes | No |
| 18394017 | TUNABLE NEURONAL NETWORK AND AN ARTIFICIAL EYE | December 2023 | November 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18381072 | CLOSED-LOOP SYSTEM FOR GROWTH OF AQUATIC BIOMASS AND GASIFICATION THEREOF | October 2023 | April 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18379644 | METHOD FOR INFECTING CELLS WITH VIRUS | October 2023 | March 2025 | Allow | 17 | 3 | 1 | No | No |
| 18469239 | TREATED DRIED BLOOD SAMPLE FOR DETECTION OF HEAVY METALS IN DRIED BLOOD | September 2023 | July 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18464101 | METHODS OF USING NATURAL AND ENGINEERED ORGANISMS TO PRODUCE SMALL MOLECULES FOR INDUSTRIAL APPLICATION | September 2023 | June 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18451071 | A PHOSPHOLIPID COMPOSITION AND ITS USE IN THE NANO LIQUID PRODUCT CONTAINING CURCUMIN HAVE THE ABILITY TO TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALING | August 2023 | February 2025 | Abandon | 18 | 3 | 0 | No | No |
| 18362294 | DESIGNED BACTERIAL COMPOSITIONS | July 2023 | November 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18358637 | METHOD AND SYSTEM FOR PRODUCTION OF ADENOSINE TRIPHOSPHATE | July 2023 | January 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18324518 | IDENTIFYING STATUS OF MALE FERTILITY BY DETERMINING SPERM CAPACITATION | May 2023 | May 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18198732 | METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY | May 2023 | September 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18316945 | COMPOSITIONS FOR THE TREATMENT OF NON-ARTICULAR CARTILAGE-ASSOCIATED BONE CONDITIONS | May 2023 | October 2024 | Abandon | 17 | 2 | 1 | No | No |
| 18306483 | COMPOSITION AND METHODS FOR TREATMENT OR PROPHYLAXIS OF CORONAVIRUS AND CANCERS | April 2023 | March 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18194632 | PERISTALTIC PROPULSION DEVICE AND SYSTEM AND METHODS OF USE THEREOF | April 2023 | June 2025 | Abandon | 27 | 3 | 1 | No | No |
| 18120313 | METHOD FOR RETROFITTING AN EXISTING PLANT WITH A BRAN FRACTIONATION PROCESS | March 2023 | September 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18171694 | TISSUE ORGANOIDS | February 2023 | March 2026 | Abandon | 37 | 4 | 1 | Yes | No |
| 18111702 | Method of Enhancing Mental Function and Acuity by Delivering Biochemical Scaffolds | February 2023 | June 2023 | Allow | 4 | 1 | 0 | No | No |
| 18169061 | COMPOSITIONS FOR INHIBITING ANAEROBIC MICROORGANISMS | February 2023 | March 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18169073 | TREATMENT OF INFLAMMATORY BOWEL DISEASES THROUGH ADMINISTRATION OF ENTERIC AEROBIZATION THERAPY | February 2023 | March 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18169095 | METHODS FOR INHIBITING ANAEROBIC MICROORGANISMS | February 2023 | February 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18098377 | EXTRACELLULAR VESICLES FROM PREVOTELLA | January 2023 | July 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18058660 | COMBINATION OF PHARMACOLOGICAL AND MICROFLUIDIC FEATURES FOR IMPROVED PLATELETS PRODUCTION | November 2022 | February 2025 | Abandon | 27 | 2 | 0 | No | No |
| 17976341 | Methods for Managing Adverse Events in Patient Populations Requiring Transfusion | October 2022 | March 2025 | Abandon | 29 | 3 | 1 | Yes | No |
| 17961836 | Biochemical Scaffolds for Modulating Cell Function | October 2022 | January 2023 | Allow | 4 | 1 | 0 | No | No |
| 17868079 | AQUEOUS SOLUTION OF BURLULIPASE COMPRISING CALCIUM IONS | July 2022 | July 2025 | Abandon | 36 | 5 | 1 | Yes | Yes |
| 17852965 | METHOD FOR PRODUCING MALTITOL, WITH AN INCREASED YIELD | June 2022 | July 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17789653 | Mammalian Cells Secreting GDNF and Their Therapeutic Use | June 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17789128 | COMBINATION OF A PROTEASOME INHIBITOR AND A HDAC INHIBITOR AND ITS USE FOR THE TREATMENT OF GENETIC DISEASES LINKED TO A PROTEIN CONFORMATIONAL DISORDER | June 2022 | February 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17837763 | PREVENTING ADHESION OF BACTERIA | June 2022 | March 2026 | Abandon | 45 | 4 | 0 | No | Yes |
| 17804211 | FLUIDIC PROCESSING WORKSTATION | May 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17748664 | METHOD FOR INFECTING CELLS WITH VIRUS | May 2022 | July 2023 | Allow | 14 | 1 | 1 | No | No |
| 17737578 | COAGULOGEN-FREE CLARIFIED LIMULUS AMEBOCYTE LYSATE | May 2022 | March 2025 | Allow | 34 | 4 | 0 | Yes | Yes |
| 17732639 | Biochemical Scaffolds for Modulating Cell Function | April 2022 | July 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17729608 | METHOD FOR PRODUCING A CULTURED CELL SHEET FOR TISSUE REGENERATION | April 2022 | June 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17655485 | METHODS OF PREPARING PH-STABILIZED AND HEAT-STERILIZED ORGAN PRESERVATION AND/OR PERFUSION SOLUTIONS | March 2022 | October 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17674831 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTICOAGULANT-INDUCED COAGULOPATHY | February 2022 | May 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17673773 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTIPLATELET-INDUCED COAGULOPATHY | February 2022 | November 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17633936 | CELL CULTURING METHOD USING SMALL-PIECE POROUS MEMBRANE | February 2022 | January 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17665753 | FREEZE-DRIED POLYMER COMPOSITIONS FOR MIXING WITH PLATELET RICH PLASMA TO FORM IMPLANTS FOR TISSUE REPAIR AND/OR COMPOSITIONS FOR THERAPEUTIC INTRA-ARTICULAR INJECTIONS | February 2022 | August 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17650220 | VIRAL CONJUNCTIVITIS TREATMENT USING RANPIRNASE AND/OR AMPHINASE | February 2022 | March 2026 | Abandon | 49 | 4 | 1 | No | No |
| 17650055 | TREATMENT OF INFLAMMATORY BOWEL DISEASES THROUGH ADMINISTRATION OF ENTERIC AEROBIZATION THERAPY | February 2022 | February 2024 | Allow | 24 | 2 | 0 | No | No |
| 17556985 | IMMUNOTHERAPY FOR OPIOID ADDICTION | December 2021 | October 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17619755 | DECELLULARIZATION METHOD | December 2021 | July 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17542021 | GLUCOSE-RESPONSIVE INSULIN DELIVERY MICRONEEDLE SYSTEM | December 2021 | March 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17533269 | METHOD OF TREATING CORNEAL PATHOLOGIES WITH OPHTHALMIC COMPOSITION OF UMBILICAL CORD BLOOD PLASMA | November 2021 | January 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17530693 | SPALAX FIBROBLAST-DERIVED ANTI-CANCER AGENTS | November 2021 | August 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17521607 | ALKYLAMINE FUNCTIONALISED SUBSTRATE FOR DELIVERING CELLS TO A SITE AND METHODS OF USE OF THE FUNCTIONALISED SUBSTRATE | November 2021 | January 2026 | Abandon | 51 | 6 | 1 | Yes | No |
| 17521401 | WET GRANULATED CELL CULTURE MEDIUM AND PREPARATION METHOD THEREFOR | November 2021 | December 2024 | Allow | 37 | 0 | 0 | Yes | No |
| 17519252 | Composition For Inhibiting Proliferation of Influenza Virus | November 2021 | December 2022 | Abandon | 13 | 2 | 0 | Yes | No |
| 17607773 | USE OF CAP-SCORE IN IDENTIFICATION OF A REPRODUCTIVE APPROACH IN MEN SUFFERING FROM VARICOCELE | October 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17607146 | Cultivation and Treatment of Plants for the Production of Plant-Derived Drugs | October 2021 | November 2025 | Allow | 49 | 5 | 1 | Yes | No |
| 17480273 | OPTIMIZED METHOD FOR PRODUCING A COMPOSITION CONTAINING ISOMALTULOSE | September 2021 | November 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17440266 | METHODS OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS | September 2021 | August 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17477019 | CLOSED SYSTEM DEVICE AND METHODS FOR GAS PERMEABLE CELL CULTURE PROCESS | September 2021 | August 2023 | Allow | 23 | 1 | 0 | Yes | No |
| 17412523 | COMPOSITION AND METHOD FOR TREATING OR PROPHYLAXIS OF CORONAVIRUS AND CANCERS | August 2021 | February 2025 | Allow | 42 | 3 | 1 | Yes | Yes |
| 17431818 | SOLUTIONS AND METHODS FOR ORGAN PRESERVATION | August 2021 | July 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17398328 | Method for Generating Human Multipotent Mammary Stem Cells From Normal Primary Breast Luminal Cells | August 2021 | August 2023 | Allow | 24 | 1 | 0 | No | No |
| 17264148 | METHOD FOR FABRICATING MULTI-LAYERED CELL SHEET AND MULTI-LAYERED SHEET FABRICATED BY USING THE SAME | August 2021 | February 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17425687 | TREATING THE CAUSATIVE AGENT IN ADHESIOGENESIS | July 2021 | February 2026 | Abandon | 55 | 2 | 1 | No | No |
| 17362524 | INHIBITION AND TREATMENT OF GASTROINTESTINAL BIOFILMS | June 2021 | September 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17418713 | COMPOSITION FOR CONVERTING INSULIN PRECURSOR INTO INSULIN ENZYME AND METHOD FOR CONVERTING INSULIN PRECURSOR INTO INSULIN BY USING SAME | June 2021 | January 2025 | Abandon | 43 | 3 | 1 | No | No |
| 17304447 | ENTERIC AEROBIZATION THERAPY | June 2021 | November 2023 | Allow | 29 | 6 | 0 | Yes | No |
| 17343349 | SEPARATION OF WAX AND FIBERS FROM PLANTS | June 2021 | September 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17340172 | COMPOSITIONS FOR PROTECTING SKIN COMPRISING DNA REPAIR ENZYMES AND PHYCOBILIPROTEIN | June 2021 | December 2025 | Abandon | 54 | 3 | 1 | Yes | No |
| 17326442 | METHOD AND AN APPARATUS FOR AN ENZYMATIC HYDROLYSIS, A LIQUID FRACTION AND A SOLID FRACTION | May 2021 | February 2025 | Allow | 44 | 3 | 1 | Yes | No |
| 17291065 | METHOD FOR ASSESSING THE ABILITY OF A SUBSTANCE OR OF A COMPOSITION TO PREVENT, SLOW OR ELIMINATE THE SIGNS OF AGEING OF THE SKIN OR OF THE LIPS | May 2021 | September 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17241310 | IMMUNOTOLERANCE WITH HEAT SHOCK PROTEINS | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17235646 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF NEUROLOGICAL AND MENTAL HEALTH DISORDERS | April 2021 | November 2025 | Abandon | 55 | 4 | 1 | No | No |
| 17234728 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF ANTIVIRAL AGENTS | April 2021 | August 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17285705 | ANTI-PATHOGENIC ACTIVITY OF A BIFUNCTIONAL PEPTIDOGLYCAN/CHITIN HYDROLASE | April 2021 | June 2025 | Allow | 50 | 5 | 0 | Yes | No |
| 17279820 | METHODS AND COMPOSITIONS FOR BIOPROTECTION OF TOMATOES FROM CLAVIBACTER MICHIGANENSIS SUBSP. MICHIGANENSIS | March 2021 | August 2025 | Abandon | 53 | 4 | 1 | Yes | No |
| 17197125 | METHODS FOR COLLECTING AND TESTING BACTERIA CONTAINING SAMPLES FROM WITHIN THE GASTROINTESTINAL TRACT | March 2021 | October 2022 | Allow | 19 | 3 | 1 | Yes | No |
| 17186344 | COMPOSITIONS AND METHODS FOR ASSESSING TOXICITY USING DYNAMIC BH3 PROFILING | February 2021 | December 2023 | Abandon | 33 | 1 | 1 | No | No |
| 17182964 | Detection of Reversal of an Anticoagulant Using a Clotting Assay | February 2021 | December 2025 | Abandon | 58 | 5 | 1 | Yes | No |
| 17165718 | DETECTION AND ISOLATION OF MYELOID-DERIVED SUPPRESSOR CELL SUBPOPULATIONS | February 2021 | July 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17262556 | METHODS FOR PRECISION THERAPEUTIC TARGETING OF HUMAN CANCER CELL MOTILITY AND KITS THEREOF | January 2021 | February 2026 | Abandon | 60 | 2 | 2 | No | No |
| 16973929 | Recombinant Protease Inhibitor-Containing Compositions, Methods for Producing Same and Uses Thereof | December 2020 | October 2025 | Abandon | 58 | 3 | 1 | No | Yes |
| 17114486 | METHODS AND KITS FOR TOPICAL APPLICATION, REMOVAL, AND INACTIVATION OF THERAPEUTIC OR COSMETIC TOXIN COMPOSITIONS | December 2020 | January 2026 | Abandon | 60 | 4 | 0 | No | Yes |
| 17077770 | BIFIDOBACTERIA FOR REDUCING FOOD, ENERGY AND/OR FAT INTAKE | October 2020 | June 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17071303 | Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof | October 2020 | January 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17038391 | ADMINISTRATION OF ASTAXANTHIN FOR MUSCLE ATROPHY | September 2020 | October 2023 | Abandon | 37 | 2 | 0 | No | No |
| 17032811 | DISPOSABLE SENSOR CHIP WITH REAGENT INCLUDING 2-SUBSTITUTED BENZOTHIAZOLYL-3-SUBSTITUTED PHENYL-5-SUBSTITUTED SULFONATED PHENYL-2H-TETRAZOLIUM SALT | September 2020 | May 2023 | Allow | 31 | 1 | 0 | No | No |
| 17032893 | Probiotic Delivery Systems | September 2020 | September 2024 | Abandon | 47 | 3 | 1 | No | No |
| 16981181 | COMPOSITIONS AND METHODS FOR TREATING THYROID EYE DISEASE | September 2020 | December 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 17000285 | AUTOMATED YEAST BUDDING MEASUREMENT | August 2020 | June 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16943487 | PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | July 2020 | November 2022 | Allow | 27 | 0 | 0 | Yes | No |
| 16942415 | MICROWELL PLATE WITH LAMINATED MICRO EMBOSSED FILM BOTTOM | July 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16936025 | ENHANCED VIRAL DELIVERY FORMULATION | July 2020 | July 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16961098 | Cell Reprogramming Therapy | July 2020 | June 2024 | Abandon | 47 | 0 | 1 | No | No |
| 16917450 | Methods of Using Natural and Engineered Organisms to Produce Small Molecules for Industrial Application | June 2020 | November 2023 | Abandon | 40 | 2 | 0 | No | No |
| 16955726 | ERYTHROCYTES FOR DRUG DELIVERY | June 2020 | June 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16898203 | CLOSED-LOOP SYSTEM FOR GROWTH OF AQUATIC BIOMASS AND GASIFICATION THEREOF | June 2020 | December 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16895903 | PREVENTIVE OR THERAPEUTIC AGENT FOR MUSCLE INJURY | June 2020 | November 2024 | Abandon | 53 | 4 | 0 | Yes | No |
| 16885651 | MEMBRANOUS TISSUE WITH EVENLY SPACED ELEVATED PROJECTIONS ON ONE SIDE AND CONCAVE DEPRESSIONS ON THE OTHER SIDE METHOD AND USE | May 2020 | May 2023 | Abandon | 36 | 2 | 1 | Yes | No |
| 16839204 | Drug Delivery System Comprising Nanocarrier Loaded with Urate Oxidase and Metal-Based Nanoparticle Capable of Degrading Hydrogen Peroxide and Pharmaceutical Composition Comprising the Same | April 2020 | November 2023 | Abandon | 44 | 2 | 1 | Yes | No |
| 16840255 | HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME FOR DETERMINING THE ETIOLOGY OF PERI-ORBITAL PUFFINESS | April 2020 | November 2021 | Allow | 20 | 5 | 0 | No | No |
| 16836068 | INTEGRATED SYSTEM FOR THE CULTIVATION OF ALGAE OR PLANTS AND THE PRODUCTION OF ELECTRIC ENERGY | March 2020 | July 2023 | Abandon | 40 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MARTIN, PAUL C.
With a 32.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MARTIN, PAUL C works in Art Unit 1653 and has examined 763 patent applications in our dataset. With an allowance rate of 41.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner MARTIN, PAUL C's allowance rate of 41.2% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MARTIN, PAUL C receive 2.77 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MARTIN, PAUL C is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +22.8% benefit to allowance rate for applications examined by MARTIN, PAUL C. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 12.6% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 19.1% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 64.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 51% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 54.1% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 55.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 84.2% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.